Figure 4
From: Antiviral activity of the EB peptide against zoonotic poxviruses
In vivo activity of EB. Ten female BALB/c mice were inoculated intranasally with 20 μL containing 105 PFU VACV (Control) or 105 PFU VACV mixed with10 mg/kg EB (Single dose) in PBS on day 0. One additional group of animals received a second dose of EB intranasally on day 3 (Two doses). Animal survival was monitored for 21 days, and mice were euthanized when they met established endpoint criteria.